SGLT inhibition and euglycaemic diabetic ketoacidosis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Lancet Diabetes and Endocrinology

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S2213-8587(15)00204-1PMID 26025388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient

  2015cited by this paper
• Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

  2014cited by this paper
• Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

  2014cited by this paper
• Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

  2014cited by this paper
• SGLT inhibition in patients with type 1 diabetes.

  2014cited by this paper
• Diabetes mellitus secondary to pancreatic diseases (Type 3c)--are we neglecting an important disease?

  2013cited by this paper

• Inhibidores del cotransportador de sodio-glucosa tipo 2

  2025cites this paper
• Euglycaemic diabetic ketoacidosis and its risk factors in patients undergoing coronary artery bypass grafting surgery: a single-centre nested case-control study in China

  2025cites this paper
• Ketoacidosis and SGLT2 Inhibitors: A Narrative Review

  2024cites this paper
• Le diabétique en périopératoire

  2024cites this paper
• Treatment of acromegaly-induced diabetes: an updated proposal

  2024cites this paper
• Euglycemic Diabetic Keto Acidosis Presentation in Association with SGLT-2 Inhibitor- Dapagliflozin

  2022cites this paper
• A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.

  2022cites this paper
• Downregulated miR-18a and miR-92a synergistically suppress non-small cell lung cancer via targeting Sprouty 4

  2022cites this paper
• Simplification of complex insulin therapy A story of dogma and therapeutic resignation.

  2021cites this paper
• Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period.

  2021cites this paper
• Euglycemic Diabetic Ketoacidosis in a Diabetic Patient Treated with SGLT2 Inhibitor

  2021cites this paper
• Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report

  2021cites this paper
• Seven-day fasting as a multimodal complex intervention for adults with type 1 diabetes: Feasibility, benefit and safety in a controlled pilot study.

  2021cites this paper
• Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial

  2021cites this paper
• Follow‐up of Patients with Chronic Pancreatitis in Clinical Practice

  2021cites this paper
• Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes

  2020cites this paper
• Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation

  2020cites this paper
• Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital

  2020cites this paper
• Seven-day Fasting as a multimodal complex interventionfor Adults with Type 1 Diabetes – Feasibility, Bene�t and Safety in a Controlled Pilot StudyFeasibility of Fasting for Adults with Type 1 Diabetes

  2020cites this paper
• Seven-day Fasting as a multimodal complex intervention for Adults with Type 1 Diabetes – Feasibility, Bene�t and Safety in a Controlled Pilot Study

  2020influential citation
• Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes

  2019cites this paper
• Circulating osteocalcin: A potential predictor of ketosis in type 2 diabetes

  2019influential citation
• ADVANCED JOURNAL OF EMERGENCY MEDICINE. 2020;4(*): e*

  2019cites this paper
• Euglycemic diabetic ketoacidosis.

  2019cites this paper
• Glycemic Management in the Operating Room: Screening, Monitoring, Oral Hypoglycemics, and Insulin Therapy

  2019cites this paper
• Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018

  2019cites this paper
• Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A randomized, open‐label, prospective study

  2019cites this paper
• Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.

  2019cites this paper
• A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition.

  2019cites this paper
• Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases

  2019cites this paper
• [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].

  2019cites this paper
• A single center retrospective analysis of SGLT2i-associated diabetic ketoacidosis in Bangkok: The role of point-of-care blood ketone testing

  2018cites this paper
• Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report.

  2018cites this paper
• Sodium‐glucose co‐transporter‐2 inhibitors and diabetic ketoacidosis: An updated review of the literature

  2018cites this paper
• When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy

  2018cites this paper
• DECLARE‐TIMI 58: Participants’ baseline characteristics

  2018influential citation
• A case series of DKA occurring in patients receiving treatment with SGLT‐2 inhibitors

  2018cites this paper
• Sodium‐glucose co‐transporter type‐2 inhibitors: pharmacology and peri‐operative considerations

  2018cites this paper
• Dapagliflozin-Associated Diabetic Ketoacidosis.

  2018cites this paper
• SGLT inhibition: a possible adjunctive treatment for type 1 diabetes

  2018cites this paper
• SGLT2 inhibitors in Type 1 diabetes: is this the future?

  2018cites this paper
• Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis

  2018cites this paper
• MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer.

  2018cites this paper
• Relationship Between Euglycemic Diabetic Ketoacidosis and SGLT-2 Inhibitors

  2018cites this paper
• Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia

  2018cites this paper
• Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin

  2017cites this paper
• Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin

  2017cites this paper
• Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor

  2017cites this paper
• Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling.

  2017cites this paper
• Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

  2017cites this paper
• Durability of response to dapagliflozin: a review of long-term efficacy and safety

  2017cites this paper
• Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives

  2017cites this paper
• Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.

  2017cites this paper
• Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale

  2017cites this paper
• Euglycemic Diabetic Ketoacidosis: A Review.

  2017cites this paper
• SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature

  2017cites this paper
• SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus

  2017cites this paper
• Management of Endocrine Failure in Chronic Pancreatitis

  2016cites this paper
• Sodium–Glucose Cotransporter 2 Inhibitors and Euglycemic Diabetic Ketoacidosis: Metabolic Acidosis With a Twist

  2016cites this paper
• A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures

  2016cites this paper
• Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition

  2016cites this paper
• SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.

  2016cites this paper
• Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin

  2016cites this paper
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

  2016cites this paper
• The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management.

  2016cites this paper
• Sodium–glucose cotransporter 2 inhibitors and diabetic ketoacidosis

  2016cites this paper
• Possible risk factors for the development of sodium-glucose co-transporter 2 inhibitor- associated diabetic ketoacidosis in type 2 diabetes

  2016cites this paper
• Gliflozin monotherapy for type 2 diabetes: a review of NICE Technology Appraisal 390

  2016cites this paper
• Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus

  2016cites this paper
• Canagliflozin-Induced Diabetic Ketoacidosis

  2016cites this paper
• Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.

  2015cites this paper
• SGLT2 inhibition and ketoacidosis – should we be concerned?

  2015cites this paper
• Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

  2015cites this paper
• Diabetische Ketoazidosen unter Canagliflozin

  2015cites this paper
• Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight

  2015cites this paper
• Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors

  2015influential citation
• SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?

  2015cites this paper
• The effect of GLP-1 analogue based therapy on hepatic fat quantity - a prospective observational study.

  2014cites this paper
• Vascular Health and Risk Management Dovepress Prevalence of Cardiovascular Risk Factors among Workers at a Private Tertiary Center in Angola

  year unknowncites this paper